Body mass index and adverse cardiovascular events in individuals with atrial fibrillation taking oral anticoagulants: a prospective, observational, long-term follow-up cohort study
Medical Studies · 29.06.2026 · 42 (2) · 214-223
DOI: 10.5114/ms.2026.162455 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Medical Studies, online erschienen am 29.06.2026. Verfasst von Łukasz Turek und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Introduction
Obesity is a known variable associated with increased risk of atrial fibrillation (AF); however, the impact of body mass index (BMI) on adverse cardiovascular outcomes in individuals with AF taking anticoagulants is not well established.
Aim
This study aimed to evaluate the association between BMI categories (normal weight, overweight, and obese) and adverse cardiovascular outcomes in individuals with AF taking anticoagulants. Material and methods This prospective, observational, long-term follow-up cohort study included 500 individuals with AF who underwent transoesophageal echocardiography before electrical cardioversion. Individuals were stratified by BMI and followed up for a median of 1927.5 days. Endpoints included major cardiovascular events (stroke, myocardial infarction, transient ischaemic attack, systemic thromboembolism, hospitalisation for heart failure, and cardiovascular death) and left atrial appendage thrombus (LAAT).
Results
Adverse cardiovascular event rates were similar across BMI categories. Individuals with normal weight presented with fewer comorbidities, such as diabetes mellitus and arterial hypertension, and demonstrated more favourable echocardiographic measurements, including smaller left atrial diameters. Despite these differences, no significant variations in LAAT prevalence or other adverse cardiovascular outcomes were observed between the BMI groups. BMI did not significantly influence long-term adverse cardiovascular outcomes or LAAT in individuals with AF taking anticoagulants. The low proportion of normal-weight individuals in the cohort suggests a potential protective role of normal weight against AF.
Conclusions
Further research is required to understand the complex interplay among BMI, comorbidities, and cardiovascular risk. These findings question the utility of BMI as a standalone risk predictor in this population.
Zitieren
APA
Turek, Ł., Sadowski, M., Kurzawski, J., Zadnecki, Ł., & Janion, M. (2026). Body mass index and adverse cardiovascular events in individuals with atrial fibrillation taking oral anticoagulants: a prospective, observational, long-term follow-up cohort study. Medical Studies, 42(2), 214-223. https://doi.org/10.5114/ms.2026.162455
Vancouver
Turek Ł, Sadowski M, Kurzawski J, Zadnecki Ł, Janion M. Body mass index and adverse cardiovascular events in individuals with atrial fibrillation taking oral anticoagulants: a prospective, observational, long-term follow-up cohort study. Medical Studies. 2026;42(2):214-223. doi:10.5114/ms.2026.162455
BibTeX
@article{Turek2026,
author = {Turek, Łukasz and Sadowski, Marcin and Kurzawski, Jacek and Zadnecki, Łukasz and Janion, Marianna},
title = {Body mass index and adverse cardiovascular events in individuals with atrial fibrillation taking oral anticoagulants: a prospective, observational, long-term follow-up cohort study},
journal = {Medical Studies},
year = {2026},
volume = {42},
number = {2},
pages = {214--223},
doi = {10.5114/ms.2026.162455}
}
EUVIMED